Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data

The BEVERLY-2 single-arm phase II trial assessed the efficacy and safety of combining neoadjuvant chemotherapy with bevacizumab and trastuzumab for the treatment of HER2-positive inflammatory breast cancer (IBC). Here, we report the results of a preplanned survival analysis at 3 years of follow-up,...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2015-03, Vol.21 (6), p.1298-1304
Main Authors: Pierga, Jean-Yves, Petit, Thierry, Lévy, Christelle, Ferrero, Jean-Marc, Campone, Mario, Gligorov, Joseph, Lerebours, Florence, Roché, Henri, Bachelot, Thomas, Charafe-Jauffret, Emmanuelle, Bonneterre, Jacques, Hernandez, Juana, Bidard, François-Clément, Viens, Patrice
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - therapeutic use
Biomarkers, Tumor - blood
Cyclophosphamide - therapeutic use
Epirubicin - therapeutic use
Female
Fluorouracil - therapeutic use
Humans
Inflammatory Breast Neoplasms - drug therapy
Inflammatory Breast Neoplasms - mortality
Inflammatory Breast Neoplasms - surgery
Middle Aged
Neoadjuvant Therapy
Neoplastic Cells, Circulating - drug effects
Prognosis
Receptor, ErbB-2 - metabolism
Survival Rate
Taxoids - therapeutic use
Trastuzumab - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The BEVERLY-2 single-arm phase II trial assessed the efficacy and safety of combining neoadjuvant chemotherapy with bevacizumab and trastuzumab for the treatment of HER2-positive inflammatory breast cancer (IBC). Here, we report the results of a preplanned survival analysis at 3 years of follow-up, along with the association between outcome and circulating biomarkers and pathologic complete response (pCR). Patients received fluorouracil, epirubicin, cyclophosphamide, and bevacizumab (cycles 1-4) and docetaxel, trastuzumab, and bevacizumab (cycles 5-8) before surgery, followed by trastuzumab and bevacizumab for 30 weeks after surgery. Circulating tumor cell (CTC) and endothelial cell (CEC) counts were assessed at baseline, cycle 5, preoperative, postoperative, and at 1 year. Fifty-two patients were included. The 3-year disease-free survival (DFS) rate was 68% and overall survival (OS) rate was 90%. pCR (centrally reviewed) was strongly associated with 3-year DFS [80% and 53% in patients with/without pCR, respectively (P = 0.03)]. CTC detection also independently predicted 3-year DFS [81% vs. 43% for patients with
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-14-1705